Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

Scott Kopetz, Sara Lonardi, Raymond S. McDermott, Massimo Aglietta, Alain Hendlisz, Michael Morse, Joseph W. Leach, Bart Neyns, Emily Chan, Franklin Chen, Ka Yeung Mark Wong, James J. Lee, Pilar Garcia-Alfonso, Andrew G. Hill, Heinz-Josef Lenz, Jayesh Desai

Research output: Contribution to journalMeeting abstract (Journal)

Abstract

Background: MMR or MSI testing is recommended for mCRC pts and is often done locally by IHC or PCR testing, respectively (NCCN V1.2017) Nivo, a fully human anti-PD-1 mAb, demonstrated durable responses and a 12-mo OS rate of 73.8% in pts with mCRC locally assessed for dMMR/MSI-H status in the CheckMate 142 study (NCT02060188; Overman M, et al. 2017). Here we describe the results of local and central testing with respect to MMR/MSI status and clinical outcomes in the CheckMate 142 study. Methods: MMR/MSI status was assessed locally on archival tumor using IHC/PCR at screening and confirmed centrally by PCR (modified Bethesda panel) testing of tumor biopsy at enrollment. dMMR was defined by IHC as a loss of expression in ≥1 mismatch repair proteins. Stable microsatellite (MSS), low MSI (MSI-L), and high MSI (MSI-H), were defined as instability in 0, 1, or ≥2 markers, respectively. Pts with dMMR/MSI-H mCRC who progressed on or were intolerant of ≥1 prior line of therapy received nivo 3 mg/kg Q2W. Results: 74 pts were dMMR/MSI-H by local testing. Of these pts, 53 (72%) were centrally confirmed as MSI-H, 7 pts had insufficient tissue sample for PCR testing, and 14 pts had a central test that did not match local test results. Of the 14 pts, 3 pts with a clinical history of LS were identified locally as dMMR but centrally as MSS (Table). INV-reported ORR was 31.1% in 74 pts locally determined as dMMR/MSI-H, 35.8% in 53 pts locally and centrally confirmed as MSI-H, and 21.4% in 14 pts not centrally confirmed as MSI-H. Conclusions: The similar clinical activity between pts locally confirmed as MSI-H and pts who were centrally confirmed as MSI-H suggest local testing is appropriate for identifying the dMMR/MSI-H pts who may benefit from nivo monotherapy. Clinical trial information: NCT02060188.

Pt Local Testing
Central Testing Clinical History of LS
Method Result
1 IHC dMMR MSS NA
2 IHC dMMR MSS No
3 IHC dMMR MSS Yes
4 IHC dMMR MSS Yes
5 IHC/PCR dMMR (IHC)/MSI-H (PCR) MSS NA
6 IHC dMMR MSS Yes
7 IHC dMMR MSS No
8 PCR MSI-H MSS NA
9 IHC/PCR dMMR (IHC)/MSI-H (PCR) MSS NA
10 IHC dMMR MSS No
11 IHC dMMR MSS NA
12 PCR MSI-H MSS NA
13 IHC dMMR MSI-L NA
14 IHC dMMR MSS NA
NA = not available.
Original languageEnglish
Pages (from-to)3548-3548
Number of pages1
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017
Event2017 ASCO Annual meeting - Chicago, United States
Duration: 2 Jun 20176 Jun 2017

Fingerprint

Dive into the research topics of 'Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.'. Together they form a unique fingerprint.

Cite this